Skip to content

Our team of highly experienced medicinal, synthetic and computational chemists have an impressive track record of progressing compounds to the clinic. Our open and unbiased mindset ensures the best strategy to quickly develop a chemical entity from an initial hit to a preclinical candidate. We are ready to tackle challenging biological targets. HTS of IRBM’s screening library, fragment screening, virtual screening as well as me-too approaches can be selected as single-strategy or in combination to generate solid starting points on challenging targets.

We are a multidisciplinary team, working closely with biologists and pharmacologists in a fully integrated research facility, that has successfully contributed to more than 100 patents and 800 academic publications.

Our combination of rational drug design and creative organic chemistry skills bolstered by computational approaches ensure we can generate novel and exciting lead series for projects in various therapeutic areas and target modalities such as classical or covalent inhibitors, allosteric modulators or degraders. We are responsive and adaptable, establishing efficient screening cascades tailored to address potential liabilities. Our goal is to efficiently and effectively progress the right molecules with optimum characteristics and potential for further therapeutic development.

We focus all our efforts on the most promising chemical entities, in terms of PK profile, with the aim of identifying orally bioavailable compounds as quickly as possible.

Relevant Publications
FIND OUT MORE ABOUT OUR CROSS FUNCTIONAL DRUG DISCOVERY SERVICES

SYNTHETIC
CHEMISTRY

COMPUTATIONAL
CHEMISTRY

COMPOUND
MANAGEMENT

COMPOUND
LIBRARIES

Back To Top